Finance

Lists
GDRX:NASDAQ
Goodrx Holdings Inc
$3.38
-0.59%
(-0.020) 1D
$3.50
+3.55% (+0.12)
After hours
Closed: Sep 18, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for GDRX...
Open
$3.36
High
$3.40
Low
$3.30
Mkt. cap
1.15B
Avg. vol.
1.57M
Volume
1.36M
P/E ratio
71.99
52-wk high
$5.81
52-wk low
$1.77
EPS
$0.05
Beta
1.59
Shares outstanding
107.18M
No. of employees
697
Open
$3.36
High
$3.40
Low
$3.30
Mkt. cap
1.15B
Avg. vol.
1.57M
Volume
1.36M
P/E ratio
71.99
52-wk high
$5.81
52-wk low
$1.77
EPS
$0.05
Beta
1.59
Shares outstanding
107.18M
No. of employees
697
News stories
From web sources and news partners
About Goodrx Holdings Inc
CEO-
Employees697
Founded2011
HeadquartersSanta Monica, California, United States
SectorHealth care
Websitegoodrx.com
Analyst ratings
Based on 10 analysts giving stock ratings to GDRX in the past 3 months
Hold
Buy
4
Hold
4
Sell
2
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for GDRX in the last 3 months.
Highest
Current $3.38
$5.00 (+47.93%)
Average
$4.21 (+24.56%)
Lowest
$2.65 (-21.60%)
Analyst
Recommendation
Action
Price target
Projected
Date
Allen Lutz
Bank of America Securities
Sell
Maintained
$2.65
-21.6%
09/15/2026
Glen Santangelo
Barclays
Sell
Maintained
$4.00
+18.3%
08/20/2026
Jailendra Singh
Truist Financial
Hold
Reiterated
-
-
08/14/2026
Kevin Caliendo
UBS
Hold
Maintained
$3.75
+10.9%
08/13/2026
Charles Rhyee
TD Cowen
Buy
Reiterated
$5.00
+47.9%
08/11/2026
Daniel Grosslight
Citi
Buy
Maintained
$5.00
+47.9%
08/11/2026
Parker Snure
Raymond James
Buy
Maintained
$4.50
+33.1%
08/07/2026
Craig Hettenbach
Morgan Stanley
Hold
Reiterated
$4.00
+18.3%
08/07/2026
Eric Sheridan
Goldman Sachs
Hold
Reiterated
$4.00
+18.3%
08/07/2026
Michael Cherny
Leerink Partners
Buy
Maintained
$5.00
+47.9%
08/06/2026
Stan Berenshteyn
Wells Fargo
Buy
Maintained
$3.50
+3.6%
06/02/2026
George Hill
Deutsche Bank
Hold
Maintained
$3.00
-11.2%
02/27/2026
Steven Valiquette
Mizuho Securities
Hold
Maintained
$3.00
-11.2%
02/27/2026
Lisa Gill
J.P. Morgan
Hold
Downgraded
-
-
02/26/2026
Last report
Aug 6, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.08 / $0.08
+0.38%beat
Revenue / Est. (USD)
200.41M / 193.16M
+3.75%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
196.03M
194.78M
194.01M
200.41M
Cost of goods sold
13.42M
17.46M
20.16M
21.00M
Cost of revenue
13.42M
17.46M
20.16M
21.00M
Research and development expenses
31.01M
25.24M
30.18M
26.71M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
115.55M
91.96M
107.87M
106.80M
Operating expense
167.99M
140.34M
159.84M
155.78M
Total operating expenses
181.41M
157.81M
180.00M
176.78M
Operating income
14.62M
36.98M
14.01M
23.63M
Other non operating income
-
24.00K
-
625.00K
EBT including unusual items
6.10M
14.19M
5.64M
15.47M
EBT excluding unusual items
6.10M
28.49M
5.64M
15.47M
Income tax expense
4.98M
8.77M
4.47M
6.93M
Effective tax rate
81.66%
61.78%
79.27%
44.81%
Other operating expenses
-
-
-
-
Net income
1.12M
5.42M
1.17M
8.54M
Net profit margin
0.57%
2.79%
0.60%
4.26%
Earnings per share
0.08
0.09
0.07
0.08
Interest and investment income
2.31M
1.89M
1.40M
1.02M
Interest expense
-10.83M
-10.40M
-9.77M
-9.81M
Net interest expenses
-8.52M
-8.51M
-8.37M
-8.79M
Depreciation and amortization charges
21.43M
23.15M
21.79M
22.27M
EBITDA
36.05M
60.12M
35.80M
45.90M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps